Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Strategy lagged the Russell Midcap® Growth Index in the fourth quarter due to stock selection. The performance was in line with expectations for the full year. The firm believes that the Strategy underperformed in 2025 because it did not own Palantir Technologies Inc (PLTR). The Strategy focuses on achieving solid risk-a ...

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were $35.2 million, down from $38.4 million in Q4 2024. Core FFO was $0.19 per share compared to $0.18 per share in the prior year [17] - For the full year 2025, total revenues were $147.6 million, down from $164.9 million in 2024. Core FFO was $0.78 per share, which included approximately $0.09 per share of lease terminations [19] - Adjusted EBITDA for 2025 was $69 million, compared to $82.8 million in 2024 [19] - G&A expenses for 2025 were $20.3 million, slightly up from $20.1 million in 2024 [19] Business Line Data and Key Metrics Changes - In 2025, the company completed over 900,000 sq ft of leasing, following 1.1 million sq ft in 2024, indicating an improving market backdrop [4] - The average weighted average lease term (WALT) for new leases signed in 2025 was nearly 10 years, almost double the portfolio average WALT [5] - Cash rent spreads for Q4 renewals were up 12.8%, although overall rent spreads for 2025 were down 7.1% [6] Market Data and Key Metrics Changes - The lease rate improved by 600 basis points year-over-year to over 80% at year-end, with occupancy rate improving by 500 basis points to 78.7% [6] - The company entered 2026 with scheduled lease expirations totaling $11.4 million of Annualized Base Rent, down from $16.2 million in 2025 [7] Company Strategy and Development Direction - The company is undergoing a strategic options review to explore pathways to unlock shareholder value [4] - There is a focus on shifting portfolio concentration away from traditional suburban office properties towards dedicated use assets (DUAs) [11] - The company aims to improve portfolio quality, lengthen WALT, renew tenants, and fill vacant space while managing leverage prudently [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in standalone prospects and expects Core FFO to grow meaningfully in the coming years as the portfolio stabilizes [15] - The leasing momentum is seen as a result of an improving market, with a robust pipeline of over 1 million sq ft in discussion or documentation stages [7] - The company anticipates that 2025 represented a trough for Core FFO, with expectations for improvement in 2026 [29] Other Important Information - The company sold 10 properties in 2025 for approximately $81 million, including additional sales of vacant properties in early 2026 [8][9] - A new $215 million secured revolving facility was established, maturing in February 2029, providing financial flexibility [14] - The board declared a quarterly cash dividend of $0.02 per share for Q1 2026 [28] Q&A Session Summary Question: Is the leasing pipeline reflecting an overall improvement in office leasing? - Management indicated that the leasing momentum is a result of both market improvement and increased activity within their portfolio [31] Question: What is the historical success rate of converting the leasing pipeline into signed leases? - Management noted that their success rate has significantly improved over the past two years, with a notable increase in leasing activity [32] Question: Can you provide context on the Barilla transaction? - The transaction was brokered and involved a property that includes test kitchens and R&D facilities, with about half being office space [34][35] Question: What is the pace of disposing of remaining vacant properties? - Management stated that while they have sold a significant number of properties, they will evaluate future vacancies on a case-by-case basis [38] Question: What opportunities do upcoming lease maturities present? - Management expects Core FFO to grow as the portfolio stabilizes, although renewal rent increases may vary based on market conditions [41]

Indianapolis-based Elevance Health, Inc. (ELV) is one of the largest U.S. health benefits and managed care companies, providing medical, pharmacy, dental, behavioral, and care management services to government-sponsored and commercial members. With a market cap of $70.6 billion, Elevance operates nationally through its Blue Cross Blue Shield–affiliated health plans and its diversified healthcare services platform. Companies worth $10 billion or more are generally described as "large-cap stocks." Elevance ...

Core Insights - Elevance Health, Inc. announced management changes aimed at simplifying decision-making and enhancing execution across its Carelon and Health Benefits divisions [1][5] Group 1: Management Changes - Mark Kaye, the Executive Vice President and Chief Financial Officer, will now oversee Carelon, which includes pharmacy services, behavioral health, value-based care, and care delivery capabilities, crucial for the company's strategy to reduce care costs [2] - Felicia Norwood, Executive Vice President and Chief Health Benefits Officer, will lead the consolidated Health Benefits organization, integrating major Health Benefits businesses and core functions for improved coordination and operational consistency [3] - Peter D. Haytaian will transition from his role as Executive Vice President and President of Carelon effective May 4, 2026, to focus on family commitments, while serving as a Special Advisor until December 31, 2026, to ensure a smooth leadership transition [4] Group 2: Strategic Objectives - The management changes are designed to support disciplined execution and enhance clarity and coordination as the company scales its operations [5] - The consolidation of Health Benefits under a single structure is expected to strengthen coordination and execution, benefiting members and customers [6] Group 3: Company Overview - Elevance Health serves approximately 104 million consumers through a diverse portfolio of medical, pharmacy, behavioral, clinical, home health, and complex care solutions [6]

Core Insights - Elevance Health, Inc. (ELV) has a market capitalization of $76.5 billion and operates as one of the largest managed healthcare and health-insurance companies in the U.S. [1] - The company provides a range of services through its four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other [1] Stock Performance - ELV stock has underperformed compared to the broader market and its healthcare peers, declining 11.4% over the past 52 weeks and 1.7% year-to-date [2] - In comparison, the S&P 500 Index has returned 11.9% over the past year [2] - The stock has also lagged behind the State Street Health Care Select Sector SPDR Fund (XLV), which fell 8.7% over the past 52 weeks [3] Recent Earnings - On January 28, ELV shares increased by 5.9% following the release of Q4 2025 earnings, with operating revenue rising 10% year-over-year to $49.3 billion [4] - Adjusted EPS for the quarter was $3.33, exceeding expectations, driven by premium increases, Medicare Advantage growth, and strong performance in the Carelon services segment [4] - The benefit expense ratio was reported at 93.5%, an increase of 110 basis points from the previous year, attributed to higher medical costs and changes in Medicare Part D [4] Analyst Expectations - For the current year ending in December, analysts project a 15.6% decrease in EPS to $25.57 [5] - The company has met or exceeded analysts' consensus estimates in three of the last four quarters, with one miss [5] - Among 21 analysts covering the stock, the consensus rating is a "Moderate Buy," consisting of 12 "Strong Buy" ratings and nine "Holds" [5] Analyst Ratings Update - The consensus rating has become more bullish compared to two months ago, when there were 11 "Strong Buy" suggestions [7] - On February 2, JPMorgan analyst Lisa Gill raised the price target for Elevance Health to $397 from $394, maintaining an "Overweight" rating [7]

Core Viewpoint - Solventum Corporation (SOLV) is a healthcare company with a market cap of $13.9 billion, focusing on a wide range of medical and health technology products and services, having spun off from 3M's healthcare division in April 2024 [1] Financial Performance - Analysts expect SOLV to report a profit of $1.50 per share for Q4 2025, reflecting a 6.4% increase from $1.41 per share in the same quarter last year [2] - For the full year 2025, analysts project an EPS of $6.03, which is a 10% decrease from $6.70 in fiscal 2024, but an increase to $6.39 is anticipated in fiscal 2026 [3] - In Q3 2025, Solventum reported revenues of approximately $2.1 billion, showing a slight year-over-year increase and a 2.7% organic growth compared to Q3 2024 [6] Stock Performance - Over the past 52 weeks, SOLV's shares have increased by 8.6%, underperforming the S&P 500 Index's 13.7% gains and the Health Care Select Sector SPDR Fund's 11.1% returns [4] - Following the release of its earnings report, SOLV's stock rose by 7.9% intraday on November 7, indicating positive investor sentiment [7] Management Outlook - Management has raised its full-year 2025 EPS guidance to a range of $5.98 to $6.08, up from the previous outlook of $5.88 to $6.03, reflecting confidence in organic growth and cost initiatives [7] - The company has consistently exceeded earnings and revenue estimates in recent quarters, enhancing investor confidence in its growth and transformation strategies [5]

Group 1 - The Cigna Group is ranked sixth among the best investments during a recession according to a recent compilation [1] - Mizuho analyst Ann Hynes has maintained a Buy rating on Cigna Group (CI) and adjusted the price target to $325 from $307, indicating a positive outlook despite slowing healthcare utilization growth [1] - Cigna Group is a global health services company providing a range of insurance solutions and operates in over 30 countries, focusing on integrated care and pharmacy benefit management [3] Group 2 - Cigna Group is set to release its fourth quarter 2025 financial results on February 5, 2026 [2]

Core Insights - Elevance Health, Inc. is valued at approximately $76.5 billion and aims to improve health outcomes for individuals, families, and communities throughout their healthcare journey [1] - The company serves over 109 million consumers with a comprehensive portfolio that includes medical, pharmacy, behavioral, clinical, home health, and complex care solutions [2] Financial Performance - Elevance Health's total revenue for fiscal 2025 third-quarter increased by 12% year over year to $50.71 billion, surpassing consensus estimates of $49.52 billion [5] - Despite a 30% year-over-year decline in adjusted EPS to $6.03, this figure exceeded expectations of $4.98, indicating strong operational execution [6] Market Expectations - Wall Street analysts predict a nearly 17% year-over-year decline in EPS to $3.19 for the upcoming fiscal 2025 fourth-quarter earnings report [3] - Projections indicate continued pressure on earnings, with fiscal 2025 EPS expected to drop by 9.2% to $30, followed by an 8.6% decline in fiscal 2026 to $27.41 [3] Stock Performance - Elevance Health shares have decreased by 6% over the past year, contrasting with a 16% increase in the S&P 500 Index and a 20.1% rise in the SPDR S&P Health Care Services ETF [4]

Group 1 - Elevance Health will release its fourth quarter and full year 2025 financial results on January 28, 2026, at 6:00 a.m. EST [1] - A conference call to review these results and the company's outlook will take place at 8:30 a.m. EST on the same day [1] - The conference call can be accessed via specific domestic and international numbers, with a replay available from January 28, 2026, until February 27, 2026 [3] Group 2 - Elevance Health serves 109 million consumers through a diverse portfolio of healthcare solutions, including medical, pharmacy, behavioral, clinical, home health, and complex care [2] - The company's purpose is to improve the health of humanity by supporting consumers, families, and communities throughout their healthcare journey [2]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks based on financial ratios [3] - Growth Score assesses a company's future earnings and financial health to identify sustainable growth opportunities [4] - Momentum Score capitalizes on price trends and earnings outlook changes to identify favorable buying opportunities [5] - VGM Score combines the three styles to highlight stocks with the best overall potential [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically delivered an average annual return of +23.93% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Company Spotlight: Cardinal Health (CAH) - Cardinal Health is a major player in healthcare services, serving nearly 90% of U.S. hospitals and managing over 43,000 pharmaceutical shipments daily [12] - The company operates in various segments, including Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution [12] - Cardinal Health holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong growth potential [13] - The company is projected to achieve year-over-year earnings growth of 18.9% for the current fiscal year, with upward revisions in earnings estimates [13][14]